Table 1.
Clinicopathologic characteristics of breast cancers harboring oncogenic/likely oncogenic alterations affecting KIT from the MSK-IMPACT cohort
| Sample ID | Sample type | Histology | Grade/ Differentiation | ER | HER2 | KIT genetic alteration | Hotspot mutation (KIT) | KIT expression (IHC) |
|---|---|---|---|---|---|---|---|---|
| KIT1 | Metastasis | IDC-NST | Poorly differentiated | Negative | Negative | M552_Y570del | Yes | NP |
| KIT2 | Metastasis | IDC-NST | Poorly differentiated | Positive | Negative | V560_Y578del | Yes | Positive |
| KIT3 | Primary | IDC-NST | Grade 3 | Positive | Negative | V559G | Yes | NP |
| KIT4 | Metastasis | Pleomorphic ILC | Poorly differentiated | Positive | Negative | R634Q | No | NP |
| KIT5 | Metastasis | IDC-NST | Poorly differentiated | Positive | Negative | Amplification | NA | NP |
| KIT6 | Primary | IDC-NST | Grade 3 | Positive | Positive | Amplification | NA | NP |
| KIT7 | Metastasis | IDC-NST | Poorly differentiated | Positive | Negative | Amplification | NA | NP |
| KIT9 | Primary | IDC-NST | Grade 3 | Negative | Positive | Amplification | NA | NP |
| KIT10 | Primary | IDC-NST | Grade 3 | Negative | Negative | Amplification | NA | NP |
| KIT11 | Primary | IDC-NST | Grade 3 | Positive | Positive | Amplification | NA | NP |
| KIT12 | Metastasis | IDC-NST | Poorly differentiated | Negative | Negative | Amplification | NA | NP |
| KIT13 | Primary | IDC-NST | Grade 3 | Negative | Positive | Amplification | NA | NP |
| KIT14 | Primary | IDC-NST | Grade 3 | Negative | Negative | Amplification | NA | Positive |
| KIT16 | Primary | IDC-NST | Grade 3 | Negative | Negative | Amplification | NA | NP |
| KIT17 | Metastasis | IDC-NST | Poorly differentiated | Negative | Negative | Amplification | NA | Positive |
| KIT18 | Metastasis | IDC-NST | Poorly differentiated | Negative | Negative | Amplification | NA | NP |
| KIT19 | Metastasis | IDC-NST | Poorly differentiated | Negative | Negative | Amplification | NA | Positive |
| KIT20 | Primary | IDC-NST | Grade 3 | Negative | Negative | Amplification | NA | NP |
ER, estrogen receptor; IDC-NST, invasive ductal carcinoma of no special type; IHC, immunohistochemistry; ILC, invasive lobular carcinoma; NA, not applicable; NP, not performed.